What is Hikal Ltd (HIKAL) share price today?

Hikal Ltd (HIKAL) is listed on the NSE. Visit VestAI at https://www.vestai.io/stocks/HIKAL for the latest live price, technical analysis, and AI-powered insights.

How to analyse HIKAL stock?

VestAI provides comprehensive HIKAL stock analysis including RSI, MACD, Bollinger Bands, SMA trend, ROCE, debt-to-equity ratio, and smart money holdings by superstar investors.

What sector is Hikal Ltd in?

Hikal Ltd (HIKAL) is in the Healthcare sector, Pharmaceuticals industry on the NSE.

Hikal Ltd

Q: What is Hikal Ltd's Orion Score?

Hikal Ltd has an Orion Score of 41/100 (Caution) — a fundamentals-based quality & risk score. Hikal Ltd scores 41/100 (Caution) on the Orion Score — weak business quality (47), poor growth (21), weak balance-sheet safety (32) and fair valuation (61). A fundamentals-based quality & risk score, not a buy/sell recommendation.

HIKAL

NSE· Healthcare

₹241.16

+3.94 (+1.66%)

Updated 07:29 am IST

52W Low · ₹150.2252W High · ₹355.00

Mid Range

Market Cap

₹2338.03L Cr

Volume

4.50L

Prev Close

₹245.69

ISIN

INE475B01022

Orion Score

Fundamentals-based quality & risk · not a recommendation

41/100

Caution

Hikal Ltd scores 41/100 (Caution) on the Orion Score — weak business quality (47), poor growth (21), weak balance-sheet safety (32) and fair valuation (61). A fundamentals-based quality & risk score, not a buy/sell recommendation.

Quality

Growth

Safety

Value

Full Orion analysis

Risk checks

Profit converts to cash (CFO 3.4× PAT)
Low debt, comfortable interest cover
No distress, manipulation or dilution flags

Forensic accounting

Piotroski F 4/9Altman Z Safe(5.17)Beneish M Clean(-3.32)

Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check

Technical / Momentum

Price Trend

45/100

Neutral

Technical momentum companion — separate from the fundamentals-based Orion Score.

Unlock with Pro

Upgrade →

VestAI Stock Score

VALUATION

No Data

D/E unavailable

QUALITY

Low Quality

ROCE 3.4% — poor capital efficiency

MOMENTUM

Bullish

RSI 64.0 — strong momentum

Price Chart

SMA 20

SMA 50

SMA 200

Key Fundamentals

Q4 FY2026

P/E Ratio: 90.40
ROCE: 3.36%
ROE (1Y): 7.38%
D/E Ratio: —
OPM: 12.26%
TTM EPS: ₹-3.96
Dividend Yield: 53.00%
Qtrly Sales: ₹517.00 Cr
Qtrly Profit: ₹14.40 Cr

Technical Signals

Quarterly Results

Revenue & Profit in ₹ Crores

Revenue Net Profit

Quarter	Revenue	Net Profit	OPM	EPS
Q4 2026	₹517	₹14.4	12.3%	₹1.17
Q3 2026	₹490.7	₹-5.9	8.5%	₹-0.48
Q2 2026	₹316.2	₹-34.9	-10.8%	₹-2.83
Q1 2026	₹371.3	₹-22.4	-3.9%	₹-1.82
Q4 2025	₹550	₹50.2	15.6%	₹4.07

Annual P&L

Revenue & Profit in ₹ Crores (Yearly)

Revenue Net Profit

Year	Revenue	Net Profit	EBITDA	OPM
FY 2026	₹1,695.2	₹-48.8	₹147.6	3.3%
FY 2025	₹1,843.5	₹90.8	₹333.4	10.5%
FY 2024	₹1,768.7	₹69.6	₹266.3	8.5%
FY 2023	₹2,004.7	₹78.38	₹255.31	7.4%

Peer Comparison — Healthcare

Top companies in the same sector by market cap

Company	Mkt Cap	P/E	ROCE	ROE	D/E	OPM
HIKAL ★	₹2,338 Cr	90.40	3.36%	7.38%	—	12.26%
SUNPHARMASun Pharmaceutical Industries	₹4,27,609 Cr	37.32	15.73%	14.72%	0.06x	18.90%
MAXHEALTHMax Healthcare Institute	₹95,110 Cr	66.21	11.94%	14.33%	0.32x	22.56%
AUROPHARMAAurobindo Pharma Limited	₹90,029 Cr	25.94	12.55%	9.93%	0.21x	15.11%
ABBOTINDIAAbbott India Limited	₹57,724 Cr	36.63	36.14%	34.46%	0.04x	27.01%
AJANTPHARMAjanta Pharma Limited	₹41,836 Cr	39.55	27.99%	25.39%	0.06x	51.40%

Balance Sheet

All values in ₹ Crores

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	₹2,528.9	₹2,487.1	₹2,385.48	₹2,213.11
Equity	₹1,262.3	₹1,187.7	₹1,133.47	₹1,067.98
Total Debt	₹764.7	₹817.6	₹748.18	₹675.02
Cash	₹13	₹12.7	₹26.73	₹11.44
Net Debt	₹749.1	₹802.1	₹721.22	₹663
Working Capital	₹205.9	₹210	₹277.47	₹195.1

Shareholding Pattern

Q1 FY2027

Promoter

69.08%

FII

4.23%

DII

3.46%

Public

23.23%

Quarter-over-Quarter Trend

Quarter	Promoter	FII	DII	Public
Q1 FY2027	69.08% ↑	4.23% ↑	3.46% ↓	23.23% ↑
Q3 FY2026	68.85%	2.31% ↓	7.05% ↑	21.78% ↑
Q2 FY2026	68.85%	4.23% ↓	5.15% ↑	21.75% ↓
Q1 FY2026	68.85%	5.35% ↓	4.03% ↑	21.76% ↑
Q4 FY2025	68.85%	5.7% ↓	3.8% ↑	21.65% ↑
Q3 FY2025	68.85%	6.06% ↓	3.48% ↓	21.61% ↑
Q2 FY2025	68.85%	6.78% ↑	3.58% ↑	20.79% ↓
Q1 FY2025	68.85%	6.66%	3.17%	21.32%

Corporate Actions

Ex-Date	Action	Details
2026-02-17	DIVIDEND	Interim Dividend - Re 0.20 Per Share

Funds Holding This Stock

4 mutual fund schemes

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct GrowthICICI_PRUDENTIAL

1.21%

₹78 Cr

Tata Small Cap Fund Direct GrowthTATA

0.55%

₹64 Cr

Bandhan BSE Healthcare Index Fund Direct GrowthIDFC

0.05%

₹0 Cr

Motilal Oswal BSE 1000 Index Fund Direct GrowthMOTILAL_OSWAL

0.00%

₹0 Cr

Analyse HIKAL with Orion AI

Ask: "Is Hikal Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation

Analyse with Orion

Want more insights like this?

Get free stock analysis, market insights, and investment ideas delivered to your inbox.

No spam. Unsubscribe anytime.

About Hikal Ltd (HIKAL) Stock

Hikal Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE475B01022. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.